Viking Therapeutics Faces a Two-Front Obesity Race as Rivals Spend Billions
Published on 10/01/2026 at 20:40 | Editorial boerse-global.de
Novo Nordisk's decision to pay as much as $2.6 billion to Jiangsu Hengrui Pharmaceuticals for rights to an experimental weight-loss pill, reported by Reuters on Tuesday, tells investors plenty about how badly the industry's giants want a seat at the obesity table. For Viking Therapeutics, the deal lands at an awkward moment: the company has just banked a substantial cash cushion and posted encouraging maintenance data, yet the competitive bar keeps climbing.
What the Hengrui Deal Signals
The arrangement underscores the willingness of big players to write enormous checks for early-stage candidates, particularly oral alternatives that could eventually chip away at the dominance of injectable therapies. If such pills reach the market faster than expected, the commercial runway for injectable programs — including Viking's VK2735 — could narrow.
Eli Lilly added to the pressure. According to Reuters, the rival unveiled new data on Tuesday for an experimental compound that produced weight loss of nearly 21% in a late-stage trial of adults with type 2 diabetes and obesity. Progress of that magnitude from established manufacturers raises the tempo across the entire obesity field and forces smaller developers to demonstrate clear points of differentiation in their clinical profiles.
The Case for VK2735 Rests on Durability
The pivotal question for Viking's valuation is not raw efficacy alone but whether weight loss holds up when doses are spaced further apart. Roughly two weeks ago, the company released maintenance-study results for VK2735: after an induction and maintenance phase, participants dosed every two weeks retained up to 97% of the weight they had lost, while monthly dosing preserved up to 90% of the reduction over three months.
Should investors sell immediately? Or is it worth buying Viking Therapeutics?
Gastrointestinal side effects during that maintenance period tracked at placebo levels — a detail that matters as much as the efficacy numbers in day-to-day clinical use. Longer dosing intervals paired with reliable tolerability could become decisive selling points. If a new approach cannot meaningfully reduce the treatment burden compared with established options, its appeal fades; the market rewards concepts that pair high efficacy with user-friendly schedules.
A $547.8 Million War Chest
Viking has the means to keep pushing. Through an offering of common stock at $35.00 per share alongside a convertible note maturing in 2032, the company raised estimated net proceeds of roughly $547.8 million. That liquidity removes any immediate financing pressure and funds the next clinical steps.
The convertible note carries obligations of its own. It creates ongoing interest expense and, upon conversion, the risk of diluting existing shareholders. Should future trials stumble, the premium baked into the pipeline could deflate quickly.
Where the Stock Stands
In today's session the shares changed hands at EUR 28.15, down 2.3%. The stock remains 27% below its 52-week high, and the market is clearly weighing each incremental data point rather than pricing in a smooth path forward.
Viking Therapeutics at a turning point? This analysis reveals what investors need to know now.
As long as the quote holds above the 52-week low of EUR 21.84, a stabilization remains possible; a break below that level could invite further declines. The next concrete catalyst is official word on the subsequent development phases for VK2735.
The obesity treatment market promises sustained growth rates, but it demands persistent clinical conviction from developers. For Viking, the task is to confirm the maintenance-regime results in further studies — because beyond efficacy, tolerability and practical dosing intervals will ultimately decide long-term commercial success.
Ad
Viking Therapeutics Stock: New Analysis - 1 October
Fresh Viking Therapeutics information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
